Mari Nakazawa1, Mike Fang2, Catherine H Marshall3, Tamara L Lotan3,4,5, Pedro Isaacsson Velho3,6, Emmanuel S Antonarakis7. 1. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 2. Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA. 3. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 4. Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 5. Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 6. Department of Oncology, Moinhos de Vento Hospital, Porto Alegre, Brazil. 7. Department of Oncology, Masonic Cancer Center, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Abstract
BACKGROUND: Inactivating missense mutations in the SPOP gene, encoding speckle-type poxvirus and zinc-finger protein, are one of the most common genetic alterations in prostate cancer. METHODS: We retrospectively identified 72 consecutive prostate cancer patients with somatic SPOP mutations, through next-generation sequencing analysis, who were treated at the Johns Hopkins Hospital. We evaluated clinical and genomic characteristics of this SPOP-mutant subset. RESULTS: SPOP alterations were clustered in the MATH domain, with hotspot mutations involving the F133 and F102 residues. The most frequent concurrent genetic alterations were in APC (16/72 [22%]), PTEN (13/72 [18%]), and TP53 (11/72 [15%]). SPOP-mutant cancers appeared to be mutually exclusive with tumors harboring the TMPRSS2-ERG fusion, and were significantly enriched for Wnt pathway (APC, CTNNB1) mutations and de-enriched for TP53/PTEN/RB1 alterations. Patients with mtSPOP had durable responses to androgen deprivation therapy (ADT) with a median time-to-castration-resistance of 42.0 (95% confidence interval [CI], 25.7-60.8) months. However, time-to-castration-resistance was significantly shorter in SPOP-mutant patients with concurrent TP53 mutations (hazard ratio [HR] 4.53; p = 0.002), HRD pathway (ATM, BRCA1/2, and CHEK2) mutations (HR 3.19; p = 0.003), and PI3K pathway (PTEN, PIK3CA, and AKT1) alterations (HR 2.69; p = 0.004). In the castration-resistant prostate cancer setting, median progression-free survival was 8.9 (95% CI, 6.7-NR) months on abiraterone and 7.3 (95% CI, 3.2-NR) months on enzalutamide. There were no responses to PARP inhibitor treatment. CONCLUSIONS: SPOP-mutant prostate cancers represent a unique subset with absent ERG fusions and frequent Wnt pathway alterations, with potentially greater dependency on androgen signaling and enhanced responsiveness to ADT. Outcomes are best for SPOP-altered patients without other concurrent mutations.
BACKGROUND: Inactivating missense mutations in the SPOP gene, encoding speckle-type poxvirus and zinc-finger protein, are one of the most common genetic alterations in prostate cancer. METHODS: We retrospectively identified 72 consecutive prostate cancer patients with somatic SPOP mutations, through next-generation sequencing analysis, who were treated at the Johns Hopkins Hospital. We evaluated clinical and genomic characteristics of this SPOP-mutant subset. RESULTS: SPOP alterations were clustered in the MATH domain, with hotspot mutations involving the F133 and F102 residues. The most frequent concurrent genetic alterations were in APC (16/72 [22%]), PTEN (13/72 [18%]), and TP53 (11/72 [15%]). SPOP-mutant cancers appeared to be mutually exclusive with tumors harboring the TMPRSS2-ERG fusion, and were significantly enriched for Wnt pathway (APC, CTNNB1) mutations and de-enriched for TP53/PTEN/RB1 alterations. Patients with mtSPOP had durable responses to androgen deprivation therapy (ADT) with a median time-to-castration-resistance of 42.0 (95% confidence interval [CI], 25.7-60.8) months. However, time-to-castration-resistance was significantly shorter in SPOP-mutant patients with concurrent TP53 mutations (hazard ratio [HR] 4.53; p = 0.002), HRD pathway (ATM, BRCA1/2, and CHEK2) mutations (HR 3.19; p = 0.003), and PI3K pathway (PTEN, PIK3CA, and AKT1) alterations (HR 2.69; p = 0.004). In the castration-resistant prostate cancer setting, median progression-free survival was 8.9 (95% CI, 6.7-NR) months on abiraterone and 7.3 (95% CI, 3.2-NR) months on enzalutamide. There were no responses to PARP inhibitor treatment. CONCLUSIONS: SPOP-mutant prostate cancers represent a unique subset with absent ERG fusions and frequent Wnt pathway alterations, with potentially greater dependency on androgen signaling and enhanced responsiveness to ADT. Outcomes are best for SPOP-altered patients without other concurrent mutations.
Authors: Thorsten H Ecke; Horst H Schlechte; Katrin Schiemenz; Markus D Sachs; Severin V Lenk; Birgit D Rudolph; Stefan A Loening Journal: Anticancer Res Date: 2010-05 Impact factor: 2.480
Authors: Wassim Abida; Joshua Armenia; Anuradha Gopalan; Ryan Brennan; Michael Walsh; David Barron; Daniel Danila; Dana Rathkopf; Michael Morris; Susan Slovin; Brigit McLaughlin; Kristen Curtis; David M Hyman; Jeremy C Durack; Stephen B Solomon; Maria E Arcila; Ahmet Zehir; Aijazuddin Syed; Jianjiong Gao; Debyani Chakravarty; Hebert Alberto Vargas; Mark E Robson; Vijai Joseph; Kenneth Offit; Mark T A Donoghue; Adam A Abeshouse; Ritika Kundra; Zachary J Heins; Alexander V Penson; Christopher Harris; Barry S Taylor; Marc Ladanyi; Diana Mandelker; Liying Zhang; Victor E Reuter; Philip W Kantoff; David B Solit; Michael F Berger; Charles L Sawyers; Nikolaus Schultz; Howard I Scher Journal: JCO Precis Oncol Date: 2017-05-31
Authors: Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald Journal: Cancer Cell Date: 2010-06-24 Impact factor: 31.743
Authors: Sylvan C Baca; Davide Prandi; Michael S Lawrence; Juan Miguel Mosquera; Alessandro Romanel; Yotam Drier; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Mahmoud Ghandi; Eliezer Van Allen; Gregory V Kryukov; Andrea Sboner; Jean-Philippe Theurillat; T David Soong; Elizabeth Nickerson; Daniel Auclair; Ashutosh Tewari; Himisha Beltran; Robert C Onofrio; Gunther Boysen; Candace Guiducci; Christopher E Barbieri; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Alex H Ramos; Wendy Winckler; Michelle Cipicchio; Kristin Ardlie; Philip W Kantoff; Michael F Berger; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Olivier Elemento; Gad Getz; Francesca Demichelis; Mark A Rubin; Levi A Garraway Journal: Cell Date: 2013-04-25 Impact factor: 41.582
Authors: John N Weinstein; Eric A Collisson; Gordon B Mills; Kenna R Mills Shaw; Brad A Ozenberger; Kyle Ellrott; Ilya Shmulevich; Chris Sander; Joshua M Stuart Journal: Nat Genet Date: 2013-10 Impact factor: 38.330
Authors: Elena Castro; Chee Goh; Daniel Leongamornlert; Ed Saunders; Malgorzata Tymrakiewicz; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Steve Ellis; Debra Frost; Elizabeth Bancroft; Trevor Cole; Marc Tischkowitz; M John Kennedy; Jacqueline Eason; Carole Brewer; D Gareth Evans; Rosemarie Davidson; Diana Eccles; Mary E Porteous; Fiona Douglas; Julian Adlard; Alan Donaldson; Antonis C Antoniou; Zsofia Kote-Jarai; Douglas F Easton; David Olmos; Rosalind Eeles Journal: Eur Urol Date: 2014-11-06 Impact factor: 20.096
Authors: Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins Journal: Nature Date: 2012-07-12 Impact factor: 49.962
Authors: Akash Kumar; Ilsa Coleman; Colm Morrissey; Xiaotun Zhang; Lawrence D True; Roman Gulati; Ruth Etzioni; Hamid Bolouri; Bruce Montgomery; Thomas White; Jared M Lucas; Lisha G Brown; Ruth F Dumpit; Navonil DeSarkar; Celestia Higano; Evan Y Yu; Roger Coleman; Nikolaus Schultz; Min Fang; Paul H Lange; Jay Shendure; Robert L Vessella; Peter S Nelson Journal: Nat Med Date: 2016-02-29 Impact factor: 53.440